Form 4 for AGEN AGENUS INC

Accepted 2021-07-02 00:00:00 ET · period of report 2021-06-15 · accession 0000899243-21-027363 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-07-02	2021-07-02	AGEN	ARMEN GARO H	COB, CEO, Dir	A - Grant	$5.52	+2,679	733.7K	+0.4%	+$14.8K
D	2021-07-02	2021-06-15	AGEN	ARMEN GARO H	COB, CEO, Dir	A - Grant	$0.00	+1.90M	1.90M	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-02	A	A	2,679	$5.52	733,702	D	—	—	(F1) As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 2, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance. (F2) $5.52 is the closing price of our Common Stock on July 2, 2021, the payroll date for the pay period ending July 2, 2021.
2	Derivative	Stock Option	2021-06-15	A	A	1,900,000	$0.00	1,900,000	D	$3.18 · — to 2030-12-17	1,900,000 Common Stock	(F5) Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.